Tarsus Pharmaceuticals has announced a definitive agreement to acquire Alkeus Pharmaceuticals, a company focused on retinal diseases. The deal, valued at up to $800 million plus royalties, centers on the acquisition of gildeuretinol, a Phase 3 investigational therapy for Stargardt disease. This strategic move significantly expands Tarsus's pipeline and solidifies its growing presence in the specialized field of retina care.
Strategic Expansion into Retina Therapeutics
This acquisition represents a key step in Tarsus's long-term vision to become a premier eye care company by addressing significant unmet medical needs. The addition of gildeuretinol complements the capabilities Tarsus is building through its existing retina program, IRX-101. By securing a late-stage asset, the company strengthens its portfolio with a potential blockbuster therapy for a debilitating condition.
Addressing a Critical Unmet Need
Stargardt disease is an inherited retinal condition that causes progressive and irreversible loss of central vision, often beginning in childhood. Patients gradually lose the ability to read, drive, or recognize faces, severely impacting their quality of life. With no FDA-approved treatments currently available, the more than 36,000 diagnosed patients in the U.S. have limited options.
Gildeuretinol, also known as ALK-001, is a novel, once-daily oral therapy designed to target the root cause of Stargardt disease. It works by reducing the accumulation of toxic vitamin A byproducts in the retina that lead to cell damage. This mechanism aims to slow the disease's progression and preserve vision for a longer period.
Promising Clinical Development and Future Outlook
The clinical program for gildeuretinol has already yielded encouraging results across various stages of the disease. Data from studies involving over 400 individuals has shown a significant slowing of atrophic lesion growth compared to untreated groups. Furthermore, the therapy has demonstrated a strong long-term tolerability profile, with some patients treated for over seven years.
The ongoing Phase 3 NORTHSTAR trial, designed in agreement with U.S. and European regulators, is expected to enroll approximately 230 patients. Its primary endpoint will measure the rate of retinal lesion growth over a 24-month period, with a key secondary endpoint assessing visual function. Top-line results from this pivotal study are anticipated in the second half of 2029.
Financial and Transaction Details
The transaction includes an upfront consideration of approximately $450 million, comprising $270 million in cash and $180 million in Tarsus common stock. Alkeus stockholders are also eligible for up to $350 million in milestone payments tied to regulatory approval and commercial launch. The agreement is further supplemented by low single-digit tiered royalties on future net sales of the drug.
The acquisition has received unanimous approval from the boards of directors of both companies and is subject to customary closing conditions. Leadership from both Tarsus and Alkeus expressed confidence that the merger will successfully advance this important therapy for patients. The transaction is expected to be finalized in 2026 pending regulatory clearance under the Hart-Scott-Rodino Act.
The acquisition of Alkeus Pharmaceuticals by Tarsus marks a significant investment in the future of retinal disease treatment. By advancing gildeuretinol, Tarsus not only enhances its strategic position in ophthalmology but also provides a beacon of hope for thousands affected by Stargardt disease. This move underscores a commitment to innovation for patients who have long awaited a therapeutic breakthrough.